Key result
Ivabradine effectively reduced heart rate to 62.55 bpm compared to 61.45 bpm with metoprolol (p=0.041) in early post-myocardial infarction patients, with similar improvements in left ventricular ejection fraction.
Why the study?
Beta-blockers have disadvantages when managing tachycardia and heart failure after myocardial infarction, prompting comparison of ivabradine versus metoprolol.
Does ivabradine reduce heart rate and improve LVEF compared to metoprolol in post-myocardial infarction patients?
RCT (n=278)
1:1
No
Does ivabradine reduce heart rate and improve LVEF compared to metoprolol in post-myocardial infarction patients?
Ivabradine may reduce heart rate versus metoprolol post-MI; leaves open LVEF effects and requires confirmation in higher-level trials.
Background: Tachycardia and heart failure are a major concern in post myocardial infarction (PMI) patients and a therapeutic challenge. Beta blockers, the first choice drugs used have certain disadvantages. Ivabradine known to reduce heart rate was compared with Metoprolol for their benefits and side effects. The aim of the study is to analyze the effects of Ivabradine on heart rate and LVEF in comparison with Metoprolol at fixed doses over a period of 12 months from the time of discharge. Methods: 278 MI patients were grouped and observed for 12 months for the effect of Ivabradine and Metoprolol drugs on their heart rate (HR) and LVEF values. Patients with acute inferior wall STEMI, HR above 70/minute were included. All patients were on treatment for 12 months. Patients likely to develop cardio-pulmonary complications excluded. MI was confirmed on ECG and serial CK-MB/ troponin T measurements and 2D ECHO. Patients were with Holter monitors. Results: 278 patients were grouped as Ivabradine group wherein 138 patients (Ivabradine 5mg twice daily) and Metoprolol group 140 patients (Metoprolol 25 mg twice daily). All the risk factors were similar in both the groups. The mean HR and LVEF values were similar in both the groups. The range of HR was 64 to 86 beats per minute in all patients. The symptomatologies among the patients of both the groups were also similar. Reduction of HR was from 76.43±7.3 to 62.55±1.05 and in Metoprolol group from 77.51±4.50 to 61.45±2.35 beats per minute 13 (09.24%) patients from Ivabradine group and 19 (13.57%) patients from Metoprolol group showed a heart rate less than 60/bpm, others had heart beats > 60/mt. Conclusion: Ivabradine was a competitive bradycardic drug in comparison to Metoprolol in early Post MI patients. It had similar action on LVEF as Metoprolol. It could be potentially used an alternative anti-tachycardia drug with no other cardiovascular side effects and wherever â-blockers are contraindicated. Bangladesh J Medicine 2022; 33: 252-258
No takes yet. Share an insight, caveat, or question.
KS et al. (2022) conducted an RCT in Post Myocardial Infarction (n=278). Ivabradine vs. Metoprolol 25 mg twice daily was evaluated on Final heart rate at 12 months (p=0.041). Ivabradine effectively reduced heart rate to 62.55 bpm compared to 61.45 bpm with metoprolol (p=0.041) in early post-myocardial infarction patients, with similar improvements in left ventricular ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: